On June 1, Novo Nordisk fell 3.09% in regular trading, trading at $44.19/share, with trading volume of $174 million. The decline came amid broad-based selling across the pharmaceutical sector combined with mounting competitive pressures in the obesity drug market.

The pharma sector experienced widespread weakness, with Merck down 3.06%, Bristol-Myers Squibb down 3.59%, Eli Lilly down 2.43%, and Pfizer down 2.43%, dragging Novo Nordisk lower in sympathy. Beyond sector headwinds, multiple competitive threats continued to weigh on sentiment. Eli Lilly's triple agonist retatrutide demonstrated 28.3% weight loss in Phase 3 data, significantly outperforming Novo Nordisk's CagriSema at 22.7%. Additionally, Brazil recently approved the first generic version of Ozempic, marketed as Ozivy by EMS at a 30% discount to the branded product, adding pricing pressure. The competitive landscape in the obesity drug space continues to tilt toward Eli Lilly, sustaining market concerns over Novo Nordisk's pipeline competitiveness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)